Clinical Journey for Patients with Aortic Regurgitation: A Retrospective Observational Study From a Multicenter Database

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community. The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”

Nicholas S. Amoroso, MD
Assistant Professor at the Medical University of South Carolina and lead author of the study.

BACKGROUND

  • Guidelines for management of aortic regurgitation (AR) suggest grading severity of disease using echocardiographic criteria 1,2
  • Contemporary data on evaluation rates, aortic valve replacement (AVR) rates, and untreated mortality for patients stratified by degree of AR severity are lacking
    • Prior literature to date has primarily focused on outcomes and/or treatment rates in
      moderate to severe and/or severe AR 2,3

 

METHODS

  • De-identified real-world dataset (Jan 2018-Mar 2023) of 1,002,853 patients >18 years of age from 25 US institutions participating in the egnite Database (egnite, Inc., Aliso Viejo, CA, USA) with appropriate permissions
  • Outcomes: 2-year rates of evaluation by the Heart Team, rates of treatment with AVR, and mortality without AVR were assessed using Kaplan Meier estimates (results compared via log rank test)
    • Physicians were prespecified at the site level as members of the Heart Team

 

RESULTS

  • Of the 1,002,853 patients, 845,113 had documented AR severity and were included in the main study analyses
  • Median (interquartile range) time from index to death or censor was 405 (112-808) days
  • Rates of evaluation by the Heart Team (95% confidence interval [CI]) at 2 years appeared low for patients with moderate-to-severe or severe AR
    • 65.4% (63.3%-67.4%) for patients diagnosed with severe AR
    • 43.5% (41.7%-45.3%) for patients diagnosed with moderate-to-severe AR
  • Rates of AVR (95% CI) at 2 years also were low for patients with moderate-to-severe or severe AR
    • 46.5% (44.2%-48.8%) for patients diagnosed with severe AR
    • 19.4% (17.6%-21.1%) for patients diagnosed with moderate-to-severe AR
  • Mortality for patients not treated with AVR increased with greater AR severity
  • At 2 years, mortality (95% CI) was 20.7% (18.4%-23.0%) for patients with severe AR
  • Two-year mortality (95% CI) for untreated patients with a left ventricular end systolic dimension index (LVESDi) ≤25 mm/m2:
    • 17.1% (16.2%-18.19%) in moderate AR
    • 22.9% (19.3%-26.3%) for severe AR
  • For those with an LVESDi >25 mm/m2:
    • 34.3% (29.2%-39.1%) in moderate AR
    • 37.2% (24.9%-47.5%) in severe AR
  •  

CONCLUSIONS

  • Untreated patients with at least moderate AR may have poor clinical outcomes
    • Left ventricular dilatation (LVESDi >25 mm/m2) appears associated with substantial mortality, even with AR graded as “moderate”
    • These data suggest that earlier referral and assessment by the Heart Team could be beneficial
  • Despite the presence of clinically significant AR, patients are infrequently referred to the Heart Team
  • Further studies are needed to determine the timing of intervention and the most optimal management of these patients

References

1. Otto CM, et al. JACC . 2021;77:e25 e197.
2. Nishimura RA, et al. Circulation. 2014;129:e521 e643.
3. Thourani VT, et al. Structural Heart. 2021;5:608 618

Amoroso NS, Sharma RP, Généreux P, Pinto DS, Dobbles M, Thourani VH, Gillam LD. Clinical journey for patients with aortic regurgitation: A retrospective observational study from a multicenter database. Presented at: TVT 2023: The Structural Heart Summit; June 7-10, 2023; Phoenix, AZ.​​​

Follow egnite on social:

Related Articles

egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.